SLE
MCID: SYS001
MIFTS: 88

Systemic Lupus Erythematosus (SLE)

Categories: Bone diseases, Genetic diseases, Immune diseases, Nephrological diseases, Rare diseases, Skin diseases

Aliases & Classifications for Systemic Lupus Erythematosus

MalaCards integrated aliases for Systemic Lupus Erythematosus:

Name: Systemic Lupus Erythematosus 57 38 12 76 25 54 59 75 37 29 6 3 15
Lupus Nephritis 57 12 53 37 55 44 15 73
Sle 57 25 59 75 3
Disseminated Lupus Erythematosus 12 25 59
Lupus Erythematosus, Systemic 12 44 73
Systemic Lupus Erythematosus, Susceptibility to 57 6
Lupus Nephritis, Susceptibility to 57 6
Libman-Sacks Disease 25 73
Lupus Erythematosus, Systemic, Susceptibility to 40
Systemic Lupus Erythematosus Susceptibility to 57
Sle - Lupus Erythematosus, Systemic 12
Lupus Erythematosus Systemic 55
Lupus Erythematosus, Discoid 73
Lupus Erythematosus 73
Lupus Vulgaris 73
Le Syndrome 25
Lupus 25

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
complement deficiency (e.g. c2 and c4 null alleles) are susceptible to developing sle
association between hla class ii alleles and presence of autoantibodies
onset between ages 16-55
female to male ratio 8-13:1


HPO:

32
systemic lupus erythematosus:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Systemic Lupus Erythematosus

NINDS : 54 Lupus (also called systemic lupus erythematosus) is a disorder of the immune system. Normally, the immune system protects the body against invading infections and cancers. In lupus, the immune system is over-active and produces increased amounts of abnormal antibodies that attack the body's tissues and organs. Lupus can affect many parts of the body, including the joints, skin, kidneys, lungs, heart, nervous system, and blood vessels. The signs and symptoms of lupus differ from person to person; the disease can range from mild to life threatening. Initial symptoms of lupus may begin with a fever, vascular headaches, epilepsy, or psychoses. A striking feature of lupus is a butterfly shaped rash over the cheeks. In addition to headache, lupus can cause other neurological disorders, such as mild cognitive dysfunction, organic brain syndrome, peripheral neuropathies, sensory neuropathy, psychological problems (including personality changes, paranoia, mania, and schizophrenia), seizures, transverse myelitis, and paralysis and stroke.

MalaCards based summary : Systemic Lupus Erythematosus, also known as lupus nephritis, is related to systemic lupus erythematosus 16 and lupus erythematosus, and has symptoms including seizures, pruritus and exanthema. An important gene associated with Systemic Lupus Erythematosus is PTPN22 (Protein Tyrosine Phosphatase, Non-Receptor Type 22), and among its related pathways/superpathways are Systemic lupus erythematosus and Innate Immune System. The drugs Simvastatin and Sirolimus have been mentioned in the context of this disorder. Affiliated tissues include Umbilical Cord, t cells and kidney, and related phenotypes are seizures and arthritis

Disease Ontology : 12 A lupus erythematosus that is an inflammation of connective tissue marked by skin rashes, joint pain and swelling, inflammation of the kidneys and inflammation of the tissue surrounding the heart.

Genetics Home Reference : 25 Systemic lupus erythematosus (SLE) is a chronic disease that causes inflammation in connective tissues, such as cartilage and the lining of blood vessels, which provide strength and flexibility to structures throughout the body. The signs and symptoms of SLE vary among affected individuals, and can involve many organs and systems, including the skin, joints, kidneys, lungs, central nervous system, and blood-forming (hematopoietic) system. SLE is one of a large group of conditions called autoimmune disorders that occur when the immune system attacks the body's own tissues and organs.

NIH Rare Diseases : 53 Lupus nephritis is a kidney disorder that is a complication of systemic lupus erythematous (SLE), commonly known as lupus. The symptoms of lupus nephritis include blood in the urine, a foamy appearance to the urine, high blood pressure, and swelling in any part of the body. This condition typically occurs in people aged 20 to 40 years. Treatment may involve medications to suppress the immune system, dialysis, or a kidney transplant. Visit our Web page on lupus for more information and resources.

OMIM : 57 Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by production of autoantibodies against nuclear, cytoplasmic, and cell surface molecules that transcend organ-specific boundaries. Tissue deposition of antibodies or immune complexes induces inflammation and subsequent injury of multiple organs and finally results in clinical manifestations of SLE, including glomerulonephritis, dermatitis, thrombosis, vasculitis, seizures, and arthritis. Evidence strongly suggests the involvement of genetic components in SLE susceptibility (summary by Oishi et al., 2008). (152700)

CDC : 3 Lupus occurs when an unknown trigger causes a person’s own immune system to attack their tissues, damaging the tissues and producing widespread inflammation. There is no known cause or cure for lupus; however, treatments are available.

UniProtKB/Swiss-Prot : 75 Systemic lupus erythematosus: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

Wikipedia : 76 Systemic lupus erythematosus (SLE), also known simply as lupus, is an autoimmune disease in which the... more...

Related Diseases for Systemic Lupus Erythematosus

Diseases in the Lupus Erythematosus family:

Systemic Lupus Erythematosus Systemic Lupus Erythematosus 15
Systemic Lupus Erythematosus 1 Systemic Lupus Erythematosus 2
Systemic Lupus Erythematosus 3 Systemic Lupus Erythematosus 4
Systemic Lupus Erythematosus 5 Systemic Lupus Erythematosus 6
Systemic Lupus Erythematosus 7 Systemic Lupus Erythematosus 8
Systemic Lupus Erythematosus 9 Systemic Lupus Erythematosus 10
Systemic Lupus Erythematosus 11 Systemic Lupus Erythematosus 12
Systemic Lupus Erythematosus 13 Systemic Lupus Erythematosus 14
Systemic Lupus Erythematosus 16

Diseases related to Systemic Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1356)
# Related Disease Score Top Affiliating Genes
1 systemic lupus erythematosus 16 35.0 DNASE1 C4A
2 lupus erythematosus 35.0 TREX1 TNFSF4 TLR5 STAT4 PTPN22 PDCD1
3 pediatric systemic lupus erythematosus 34.7 STAT4 C4B C4A
4 vitiligo-associated multiple autoimmune disease susceptibility 1 33.8 PTPN22 PDCD1 CTLA4
5 arthritis 32.3 STAT4 PTPN22 IRF5 IL10
6 rheumatoid arthritis 32.3 STAT4 PTPN22 MALAT1 IRF5 IL10 CTLA4
7 autoimmune disease 31.9 STAT4 PTPN22 PDCD1 IRF5 IL10 FCGR2B
8 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.4 PTPN22 IL10 CTLA4
9 hemophagocytic lymphohistiocytosis 31.0 IL10 CTLA4 CR2
10 celiac disease 1 30.9 PTPN22 IL10 CTLA4
11 primary biliary cholangitis 30.8 IRF5 CTLA4
12 inflammatory bowel disease 30.7 TLR5 STAT4 PTPN22 IRF5 IL10 CTLA4
13 behcet syndrome 30.4 STAT4 IL10 CTLA4 C4A
14 systemic lupus erythematosus 1 12.8
15 systemic lupus erythematosus 2 12.8
16 systemic lupus erythematosus 10 12.8
17 systemic lupus erythematosus 6 12.7
18 systemic lupus erythematosus 9 12.7
19 systemic lupus erythematosus 11 12.6
20 systemic lupus erythematosus 3 12.5
21 systemic lupus erythematosus 4 12.5
22 systemic lupus erythematosus 5 12.5
23 systemic lupus erythematosus 7 12.5
24 systemic lupus erythematosus 12 12.5
25 neonatal systemic lupus erythematosus 12.5
26 systemic lupus erythematosus with hemolytic anemia 1 12.5
27 systemic lupus erythematosus 15 12.4
28 systemic lupus erythematosus with nephritis 1 12.4
29 systemic lupus erythematosus with nephritis 2 12.4
30 systemic lupus erythematosus with nephritis 3 12.4
31 systemic lupus erythematosus 8 12.4
32 systemic lupus erythematosus 13 12.4
33 systemic lupus erythematosus 14 12.4
34 neonatal lupus erythematosus 12.2
35 familial chilblain lupus 12.1
36 hypertrophic or verrucous lupus erythematosus 12.0
37 discoid lupus erythematosus of eyelid 11.9
38 c1q deficiency 11.8
39 mixed connective tissue disease 11.8
40 antiphospholipid syndrome, familial 11.8
41 sjogren syndrome 11.6
42 drug-induced lupus erythematosus 11.6
43 st. louis encephalitis 11.6
44 macrophage activation syndrome 11.6
45 pure red-cell aplasia 11.6
46 cutaneous lupus erythematosus 11.6
47 hypogonadotropic hypogonadism 11.6
48 complement component 2 deficiency 11.6
49 epidermolysis bullosa acquisita 11.6
50 renal tubular acidosis, distal 11.6

Comorbidity relations with Systemic Lupus Erythematosus via Phenotypic Disease Network (PDN): (show all 20)


Acute Cystitis Chronic Kidney Failure
Chronic Myocardial Ischemia Deficiency Anemia
Esophagitis Familial Atrial Fibrillation
Heart Disease Hypersensitivity Vasculitis
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Ischemic Heart Disease
Mitral Valve Disease Neutropenia
Osteoporosis Postinflammatory Pulmonary Fibrosis
Raynaud Phenomenon Rheumatoid Arthritis
Sjogren Syndrome Systemic Scleroderma

Graphical network of the top 20 diseases related to Systemic Lupus Erythematosus:



Diseases related to Systemic Lupus Erythematosus

Symptoms & Phenotypes for Systemic Lupus Erythematosus

Symptoms via clinical synopsis from OMIM:

57
Neurologic Central Nervous System:
seizures
psychosis

Hematology:
hemolytic anemia
thrombocytopenia
leukopenia

Respiratory Lung:
pleuritis

Genitourinary Kidneys:
nephritis

Laboratory Abnormalities:
antiphospholipid antibody
anti dsdna antibody
serum antinuclear antibody

Skeletal Limbs:
arthritis

Cardiovascular Heart:
pericarditis

Immunology:
systemic lupus erythematosus

Skin Nails Hair Skin:
photosensitivity
erythematous malar rash
discoid rash


Clinical features from OMIM:

152700

Human phenotypes related to Systemic Lupus Erythematosus:

32 (show all 14)
# Description HPO Frequency HPO Source Accession
1 seizures 32 HP:0001250
2 arthritis 32 HP:0001369
3 hemolytic anemia 32 HP:0001878
4 thrombocytopenia 32 HP:0001873
5 psychosis 32 HP:0000709
6 pericarditis 32 HP:0001701
7 cutaneous photosensitivity 32 HP:0000992
8 leukopenia 32 HP:0001882
9 pleuritis 32 HP:0002102
10 systemic lupus erythematosus 32 HP:0002725
11 antinuclear antibody positivity 32 HP:0003493
12 nephritis 32 HP:0000123
13 antiphospholipid antibody positivity 32 HP:0003613
14 malar rash 32 HP:0025300

UMLS symptoms related to Systemic Lupus Erythematosus:


seizures, pruritus, exanthema, heliotrope rash, lupus-like rash

MGI Mouse Phenotypes related to Systemic Lupus Erythematosus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.28 C4B CR2 CTLA4 DNASE1 ENG FCGR2A
2 homeostasis/metabolism MP:0005376 10.21 C4B CR2 CTLA4 DNASE1 ENG FCGR2B
3 immune system MP:0005387 10.17 C4B CR2 CTLA4 DNASE1 FCGR2A FCGR2B
4 cardiovascular system MP:0005385 10.16 C4B CTLA4 ENG FCGR2B IL10 PDCD1
5 digestive/alimentary MP:0005381 10.03 C4B CTLA4 ENG FCGR2B IL10 PTPN22
6 mortality/aging MP:0010768 9.97 C4B CR2 CTLA4 DNASE1 ENG FCGR2A
7 liver/biliary system MP:0005370 9.86 C4B CTLA4 FCGR2B IL10 PDCD1 PTPN22
8 renal/urinary system MP:0005367 9.56 C4B CR2 DNASE1 FCGR2B PDCD1 PTPN22
9 respiratory system MP:0005388 9.23 CTLA4 ENG FCGR2B IL10 PDCD1 PTPN22

Drugs & Therapeutics for Systemic Lupus Erythematosus

Drugs for Systemic Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 395)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 1,Early Phase 1 79902-63-9 54454
2
Sirolimus Approved, Investigational Phase 4,Phase 2 53123-88-9 46835353 6436030 5284616
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
4
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
5
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
6
Everolimus Approved Phase 4,Phase 2 159351-69-6 6442177
7
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
8
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
9
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
10
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
11
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
12
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 6055-19-2, 50-18-0 2907
13
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 118-42-3 3652
14
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1 446-86-6 2265
15
belimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 356547-88-1 5957 10451420
16
Pioglitazone Approved, Investigational Phase 4,Phase 1,Phase 2 111025-46-8 4829
17
Metformin Approved Phase 4 657-24-9 14219 4091
18
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 50-78-2 2244
19
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
20
leucovorin Approved Phase 4,Phase 3,Phase 2 58-05-9 6006 143
21
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
22
Sulfamethoxazole Approved Phase 4 723-46-6 5329
23 Lifitegrast Approved Phase 4 1025967-78-5
24
Vincristine Approved, Investigational Phase 4 57-22-7, 2068-78-2 5978
25
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
26
Lenalidomide Approved Phase 4 191732-72-6 216326
27
Thioguanine Approved Phase 4 154-42-7 2723601
28
4-Aminopyridine Approved Phase 4 504-24-5 1727
29
Calcitriol Approved, Nutraceutical Phase 4,Phase 2 32222-06-3 5280453 134070
30
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
31
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2,Phase 1,Not Applicable 50-14-6 5280793
32
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 1406-16-2
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
34
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
35 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 beta-endorphin Phase 4,Phase 2
37 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Adrenocorticotropic Hormone Phase 4,Phase 2
39 Melanocyte-Stimulating Hormones Phase 4,Phase 2
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Anticholesteremic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
42 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
43 Calcium, Dietary Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
44 Rosuvastatin Calcium Phase 4,Phase 3,Phase 2,Phase 1 147098-20-2
45 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
46 Lipid Regulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
47 Hypolipidemic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
48 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
50 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 626)
# Name Status NCT ID Phase Drugs
1 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4 quinipril
2 Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease Unknown status NCT01753401 Phase 4 Acthar;Placebo for Acthar
3 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
4 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
5 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Unknown status NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
6 Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE) Active, not recruiting NCT01632241 Phase 4 Standard therapy
7 A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
8 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus Completed NCT01322308 Phase 4 pioglitazone;placebo
9 Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED) Terminated NCT00739050 Phase 4 simvastatin;Comparator: Placebo
10 The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS Completed NCT00413361 Phase 4 versus hydroxychloroquine
11 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus Completed NCT00668330 Phase 4 Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
12 The Effect of Metformin on Reducing Lupus Flares Active, not recruiting NCT02741960 Phase 4 metformin;placebo
13 Acthar SLE (Systemic Lupus Erythematosus) Recruiting NCT02779153 Phase 4 Acthar low dose (40 U);Acthar high dose (80 U)
14 Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin;placebo
15 Belimumab Assessment of Safety in SLE Active, not recruiting NCT01705977 Phase 4
16 Levothyroxine in Pregnant SLE Patients Withdrawn NCT01276782 Phase 4 Levothyroxine
17 A Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Participants With Active Systemic Lupus Erythematosus (SLE) Recruiting NCT02953821 Phase 4 Repository corticotropin injection;Placebo gel
18 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
19 Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus Completed NCT01769937 Phase 4 H.P. Acthar Gel
20 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
21 Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE) Completed NCT01101802 Phase 4 Mycophenolate mofetil;sugar pill
22 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
23 Safety and Immunogenicity of a Zoster Vaccine in SLE Active, not recruiting NCT02477150 Phase 4
24 Efficacy of Fish Oil in Lupus Patients Completed NCT00828178 Phase 4 Omega-3
25 Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4 Azathioprine;Enteric-Coated Mycophenolate Sodium
26 Lupus Atherosclerosis Prevention Study Completed NCT00120887 Phase 4 Atorvastatin
27 The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria Withdrawn NCT00508898 Phase 4 Calcitriol;Multivitamin
28 Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Recruiting NCT03540823 Phase 4
29 The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients Withdrawn NCT01359826 Phase 4 Milnacipran
30 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Recruiting NCT02270970 Phase 4
31 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4 Long-acting tacrolimus (Advagraf, Astellas Pharma)
32 Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous Recruiting NCT03042260 Phase 4 Trimethoprim-Sulfamethoxazole;Placebo Oral Tablet
33 A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE Active, not recruiting NCT03098823 Phase 4 RAYOS;Prednisone
34 Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases Recruiting NCT03122431 Phase 4 Thalidomide;Hydroxychloroquine reduced;Hydroxychloroquine high
35 ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Withdrawn NCT01926054 Phase 4 Acthar gel
36 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
37 ACTHar in the Treatment of Lupus Nephritis Recruiting NCT02226341 Phase 4 CellCept;ACTHar gel;ACTHar gel
38 Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children Recruiting NCT01861561 Phase 4 Low-dose intravenous cyclophosphamide;High-dose intravenous cyclophosphamide
39 Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease Recruiting NCT03287635 Phase 4 Corticotropin 80Unit/Ml Repository Injection
40 Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence Recruiting NCT03592823 Phase 4 Hydroxychloroquine Sulfate 200 Mg Tablet
41 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
42 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
43 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4 Pletal
44 Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease Active, not recruiting NCT03762824 Phase 4
45 Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus Completed NCT01408199 Phase 4 Lenalidomide
46 Trial of Belimumab in Early Lupus Not yet recruiting NCT03543839 Phase 4
47 Thiopurine Induced Pancreatitis in IBD Patients Recruiting NCT02281799 Phase 4 Azathioprine
48 Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine. Recruiting NCT02849782 Phase 4 Fampridine
49 Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus Unknown status NCT02558517 Phase 3 prednisone discontinuation
50 Study of GL701 in Men With Systemic Lupus Erythematosus Unknown status NCT00037128 Phase 3 GL701

Search NIH Clinical Center for Systemic Lupus Erythematosus

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Systemic Lupus Erythematosus cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lupus nephritis

Genetic Tests for Systemic Lupus Erythematosus

Genetic tests related to Systemic Lupus Erythematosus:

# Genetic test Affiliating Genes
1 Systemic Lupus Erythematosus 29 CTLA4 DNASE1 FCGR2A FCGR2B PTPN22 TREX1

Anatomical Context for Systemic Lupus Erythematosus

MalaCards organs/tissues related to Systemic Lupus Erythematosus:

41
T Cells, Kidney, B Cells, Skin, Heart, Bone, Endothelial
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Systemic Lupus Erythematosus:
# Tissue Anatomical CompartmentCell Relevance
1 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Systemic Lupus Erythematosus

Articles related to Systemic Lupus Erythematosus:

(show top 50) (show all 9440)
# Title Authors Year
1
H-magnetic resonance spectroscopy: diagnostic tool in recurrent headache in systemic lupus erythematosus. A case report. ( 30425768 )
2019
2
Intestinal pseudo-obstruction as the initial manifestation of systemic lupus erythematosus. ( 30291036 )
2019
3
Activity and expression of E-NTPDase is altered in peripheral lymphocytes of systemic lupus erythematosus patients. ( 30409763 )
2019
4
mTOR inhibitor INK128 attenuates systemic lupus erythematosus by regulating inflammation-induced CD11b+Gr1+ cells. ( 30292636 )
2019
5
Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus. ( 30159624 )
2019
6
Immunoglobulin G subclass 3 in ISN/RPL lupus nephritis classification
. ( 30431429 )
2019
7
Lupus Nephritis. ( 30454753 )
2019
8
Acquired angioedema in juvenile systemic lupus erythematosus: case-based review. ( 29951963 )
2018
9
Anti-tubulin-I+-1C autoantibody in systemic lupus erythematosus: a novel indicator of disease activity and vasculitis manifestations. ( 29427009 )
2018
10
Analysis of relationships between 25-hydroxyvitamin D, parathyroid hormone and cathelicidin with inflammation and cardiovascular risk in subjects with paediatric systemic lupus erythematosus: an Atherosclerosis Prevention in Paediatric Lupus Erythematosus (APPLE) study. ( 29955369 )
2018
11
Retrospective analysis of the risk of hemorrhage associated with moderate and severe thrombocytopenia of 173 patients with systemic lupus erythematosus. ( 29979417 )
2018
12
The existential experience of everyday life with systemic lupus erythematosus. ( 29350776 )
2018
13
Attenuated post-exercise heart rate recovery in patients with systemic lupus erythematosus: the role of disease severity and beta-blocker treatment. ( 28650277 )
2018
14
Antibodies to extractable nuclear antigens (ENAS) in systemic lupus erythematosus patients: correlations with clinical manifestations and disease activity. ( 29976042 )
2018
15
Bronchiolitis obliterans organising pneumonia as an initial manifestation in a patient with systemic lupus erythematosus: a rare presentation. ( 29804073 )
2018
16
Limbic Encephalitis in Association with Systemic Lupus Erythematosus. ( 29780149 )
2018
17
Prevalence and factors associated with fatigue in female patients with systemic lupus erythematosus. ( 29439873 )
2018
18
[Opportunistic infection in systemic lupus erythematosus patients: the disease spectrum and the characteristics of peripheral lymphocyte subsets]. ( 29325308 )
2018
19
Complement deficiency in pediatric-onset systemic lupus erythematosus. ( 29692593 )
2018
20
Association of angiotensin-converting enzyme insertion/deletion polymorphism with susceptibility to systemic lupus erythematosus: a meta-analysis. ( 29205894 )
2018
21
Regulatory effects of four ginsenoside monomers in humoral immunity of systemic lupus erythematosus. ( 29434811 )
2018
22
Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. ( 29247540 )
2018
23
Systemic Lupus Erythematosus Presenting as Longitudinally Extensive Transverse Myelitis and Nephritis: A Case Report. ( 29872583 )
2018
24
Diffuse alveolar haemorrage as initial presentation of systemic lupus erythematosus: a case report. ( 28592199 )
2018
25
Women who had appendectomy have increased risk of systemic lupus erythematosus: a nationwide cohort study. ( 29971583 )
2018
26
A Punctate Magnetic Resonance Imaging Pattern in a Patient with Systemic Lupus Erythematosus is an Early Sign of Progressive Multifocal Leukoencephalopathy: A Clinicopathological Study. ( 29709947 )
2018
27
The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease. ( 29796907 )
2018
28
Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies. ( 28659045 )
2018
29
Antiphospholipid Antibodies and Heart Valve Disease in Systemic Lupus Erythematosus. ( 29549933 )
2018
30
Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014). ( 29121273 )
2018
31
Concordance of autoimmune disease in a nationwide Danish systemic lupus erythematosus twin cohort. ( 28755788 )
2018
32
Contribution of Socioeconomic Status to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes Among Women With Systemic Lupus Erythematosus. ( 28480528 )
2018
33
CCR6<sup>+</sup>Th cell distribution differentiates systemic lupus erythematosus patients based on anti-dsDNA antibody status. ( 29441231 )
2018
34
Primary central nervous system lymphoma in a patient with systemic lupus erythematosus mimicking high-grade glioma: A case report and review of literature. ( 29879076 )
2018
35
Pediatric Systemic Lupus Erythematosus: Learning From Longer Follow Up to Adulthood. ( 29868531 )
2018
36
Assessment of subclinical atherosclerosis in systemic lupus erythematosus: A systematic review and meta-analysis. ( 29288864 )
2018
37
Relationship between Neutrophil-to-Lymphocyte Ratio and Pulse Wave Velocity in Young Patients with Systemic Lupus Erythematosus. ( 29271374 )
2018
38
Exome sequencing revealed C1Q homozygous mutation in Pediatric Systemic Lupus Erythematosus. ( 29739689 )
2018
39
Autoimmune disease associated IFIH1 single nucleotide polymorphism related with IL-18 serum levels in Chinese systemic lupus erythematosus patients. ( 29930297 )
2018
40
Cytomegalovirus infection in a patient with systemic lupus erythematosus and acute myocardial infarction - cause or causal relationship? ( 29915649 )
2018
41
Increased incidence of cancer in systemic lupus erythematosus: a Finnish cohort study with more than 25 years of follow-up. ( 29318934 )
2018
42
Characteristics of systemic lupus erythematosus in a sample of the Egyptian population: a retrospective cohort of 1109 patients from a single center. ( 29431056 )
2018
43
Clinical Factors Associated with Brain Volume Reduction in Systemic Lupus Erythematosus Patients without Major Neuropsychiatric Manifestations. ( 29449817 )
2018
44
Papilloedema and Autoimmune Retinopathy from Systemic Lupus Erythematosus. ( 29563958 )
2018
45
Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease. ( 29670626 )
2018
46
Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus. ( 29451069 )
2018
47
B-cell-depleting therapy for diffuse alveolar hemorrhage in systemic lupus erythematosus. ( 29907447 )
2018
48
Hospital-acquired infection in patients with systemic lupus erythematosus: a case-control study in a southern Chinese population. ( 29181727 )
2018
49
Association of severe and therapy-refractory systemic lupus erythematosus and neuromyelitis optica: a management challenge. ( 29866760 )
2018
50
Impaired long-term immune protection following pneumococcal 13-valent/23-valent polysaccharide vaccine in systemic lupus erythematosus (SLE). ( 29444908 )
2018

Variations for Systemic Lupus Erythematosus

UniProtKB/Swiss-Prot genetic disease variations for Systemic Lupus Erythematosus:

75
# Symbol AA change Variation ID SNP ID
1 PTPN22 p.Arg620Trp VAR_022605 rs2476601
2 TREX1 p.Arg114His VAR_028319 rs72556554
3 TREX1 p.Ala158Val VAR_037949 rs762011967
4 TREX1 p.Gly227Ser VAR_037950 rs113107733
5 TREX1 p.Arg240Ser VAR_037951 rs72556555
6 TREX1 p.Ala247Pro VAR_037952 rs112741962
7 TREX1 p.Pro290Leu VAR_037954 rs148833270
8 TREX1 p.Tyr305Cys VAR_037955 rs370504038
9 TREX1 p.Gly306Ala VAR_037956 rs780022923
10 TREX1 p.Asp200His VAR_070901

ClinVar genetic disease variations for Systemic Lupus Erythematosus:

6 (show all 19)
# Gene Variation Type Significance SNP ID Assembly Location
1 TREX1 NM_033629.5(TREX1): c.341G> A (p.Arg114His) single nucleotide variant risk factor rs72556554 GRCh37 Chromosome 3, 48508395: 48508395
2 TREX1 NM_033629.5(TREX1): c.341G> A (p.Arg114His) single nucleotide variant risk factor rs72556554 GRCh38 Chromosome 3, 48466996: 48466996
3 FCGR2B NM_004001.4(FCGR2B): c.-386G> C single nucleotide variant risk factor rs3219018 GRCh38 Chromosome 1, 161662856: 161662856
4 FCGR2B NM_004001.4(FCGR2B): c.-386G> C single nucleotide variant risk factor rs3219018 GRCh37 Chromosome 1, 161632646: 161632646
5 FCGR2B NM_004001.4(FCGR2B): c.695T> C (p.Ile232Thr) single nucleotide variant protective,risk factor rs1050501 GRCh37 Chromosome 1, 161643798: 161643798
6 FCGR2B NM_004001.4(FCGR2B): c.695T> C (p.Ile232Thr) single nucleotide variant protective,risk factor rs1050501 GRCh38 Chromosome 1, 161674008: 161674008
7 PTPN22 NM_015967.6(PTPN22): c.1858C> T (p.Arg620Trp) single nucleotide variant risk factor rs2476601 GRCh37 Chromosome 1, 114377568: 114377568
8 PTPN22 NM_015967.6(PTPN22): c.1858C> T (p.Arg620Trp) single nucleotide variant risk factor rs2476601 GRCh38 Chromosome 1, 113834946: 113834946
9 TNF TNF, -308G-A single nucleotide variant risk factor
10 FCGR2A NM_021642.3(FCGR2A): c.497A> G (p.His166Arg) single nucleotide variant drug response rs1801274 GRCh37 Chromosome 1, 161479745: 161479745
11 FCGR2A NM_021642.3(FCGR2A): c.497A> G (p.His166Arg) single nucleotide variant drug response rs1801274 GRCh38 Chromosome 1, 161509955: 161509955
12 DNASE1 NM_005223.3(DNASE1): c.13A> T (p.Lys5Ter) single nucleotide variant risk factor rs121912990 GRCh37 Chromosome 16, 3705387: 3705387
13 DNASE1 NM_005223.3(DNASE1): c.13A> T (p.Lys5Ter) single nucleotide variant risk factor rs121912990 GRCh38 Chromosome 16, 3655386: 3655386
14 DNASE1 NM_005223.3(DNASE1): c.731G> A (p.Arg244Gln) single nucleotide variant risk factor rs1053874 GRCh37 Chromosome 16, 3707747: 3707747
15 DNASE1 NM_005223.3(DNASE1): c.731G> A (p.Arg244Gln) single nucleotide variant risk factor rs1053874 GRCh38 Chromosome 16, 3657746: 3657746
16 CTLA4 NM_005214.4(CTLA4): c.49A> G (p.Thr17Ala) single nucleotide variant Benign rs231775 GRCh37 Chromosome 2, 204732714: 204732714
17 CTLA4 NM_005214.4(CTLA4): c.49A> G (p.Thr17Ala) single nucleotide variant Benign rs231775 GRCh38 Chromosome 2, 203867991: 203867991
18 ENG NM_000118.3(ENG): c.816+6T> C single nucleotide variant Pathogenic rs759191907 GRCh38 Chromosome 9, 127825225: 127825225
19 ENG NM_000118.3(ENG): c.816+6T> C single nucleotide variant Pathogenic rs759191907 GRCh37 Chromosome 9, 130587504: 130587504

Copy number variations for Systemic Lupus Erythematosus from CNVD:

7 (show all 43)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14694 1 110000000 163800000 Gain or loss FCGR3B Systemic lupus erythematosus
2 21050 1 156500000 165500000 Copy number FCGR3B Systemic lupus erythematosus
3 21051 1 156500000 165500000 Copy number FCGR3B Systemic lupus erythematosus
4 21053 1 156500000 165500000 Copy number FCGR3B Systemic lupus erythematosus
5 21628 1 159859611 159867782 Copy number FCGR3B Systemic lupus erythematosus
6 21630 1 159859611 159867782 Low copy number FCGR3B Systemic lupus erythematosus
7 21794 1 161592989 161601158 Copy number FCGR3B Systemic lupus erythematosus
8 21797 1 161592989 161601158 Deletion FCGR3B Systemic lupus erythematosus
9 107133 17 1225928 31649829 Copy number CCL3L3 Systemic lupus erythematosus
10 107143 17 1225928 31649843 Copy number CCL3L1 Systemic lupus erythematosus
11 107163 17 1242109 31665953 Copy number CCL4L2 Systemic lupus erythematosus
12 110232 17 31562580 31665959 Copy number CCL4L1 Systemic lupus erythematosus
13 110282 17 31800000 38100000 Copy number CCL3L1 Systemic lupus erythematosus
14 110283 17 31800000 38100000 Copy number CCL3L1 Systemic lupus erythematosus
15 110288 17 31800000 38100000 Copy number CCL4L1 Systemic lupus erythematosus
16 112168 17 38100000 38400000 Copy number CCL3L1 Systemic lupus erythematosus
17 113342 17 43165608 43178484 Amplification T-bet Systemic lupus erythematosus
18 162470 22 21800000 24300000 Gain or loss GSTT1 Systemic lupus erythematosus
19 186012 4 2713184 2727859 Deletion TNIP2 Systemic lupus erythematosus
20 196060 5 158674368 158690059 Amplification IL-12B Systemic lupus erythematosus
21 204042 6 105500000 114600000 Copy number C4A Systemic lupus erythematosus
22 204043 6 105500000 114600000 Copy number C4B Systemic lupus erythematosus
23 207132 6 15200000 46200000 Copy number Systemic lupus erythematosus
24 209409 6 2614953 31491069 Copy number MICA Systemic lupus erythematosus
25 210235 6 29900000 36800000 Low copy numbers C4 Systemic lupus erythematosus
26 210494 6 30400000 36600000 Copy number C4A Systemic lupus erythematosus
27 210495 6 30400000 36600000 Copy number C4B Systemic lupus erythematosus
28 210499 6 30400000 36600000 Copy number C4A Systemic lupus erythematosus
29 210506 6 30400000 36600000 Copy number C4B Systemic lupus erythematosus
30 210507 6 30400000 36600000 Copy number C4B Systemic lupus erythematosus
31 210512 6 30400000 36600000 Gain C4A Systemic lupus erythematosus
32 210513 6 30400000 36600000 Gain C4B Systemic lupus erythematosus
33 211033 6 31949833 32003194 Copy number C4A Systemic lupus erythematosus
34 211045 6 3197570 32111174 Copy number C4A Systemic lupus erythematosus
35 211049 6 3197570 32111174 Duplication C4 Systemic lupus erythematosus
36 211054 6 31982571 32003194 Copy number C4B Systemic lupus erythematosus
37 211360 6 32593131 32665540 Copy number HLA-DRB5 Systemic lupus erythematosus
38 212285 6 3674895 32665540 Copy number HLA-DRB1 Systemic lupus erythematosus
39 212431 6 3795995 32719407 Copy number HLA-DQA1 Systemic lupus erythematosus
40 212452 6 3813334 32742444 Copy number HLA-DQB1 Systemic lupus erythematosus
41 212671 6 40500000 46200000 Copy number Systemic lupus erythematosus
42 212678 6 40500000 93100000 Copy number Systemic lupus erythematosus
43 243031 8 7752198 7754236 Copy number DEFB4 Systemic lupus erythematosus

Expression for Systemic Lupus Erythematosus

LifeMap Discovery
Genes differentially expressed in tissues of Systemic Lupus Erythematosus patients vs. healthy controls: 35 (show all 12)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFI27 interferon, alpha-inducible protein 27 Blood + 5.47 0.000
2 OTOF otoferlin Blood + 5.25 0.000
3 RPS4Y1 ribosomal protein S4, Y-linked 1 Blood - 4.40 0.000
4 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 Blood + 4.22 0.000
5 LINC00661 long intergenic non-protein coding RNA 661 Blood + 4.15 0.000
6 SIGLEC1 sialic acid binding Ig-like lectin 1, sialoadhesin Blood + 4.12 0.000
7 EIF1AY eukaryotic translation initiation factor 1A, Y-linked Blood - 3.96 0.000
8 RSAD2 radical S-adenosyl methionine domain containing 2 Blood + 3.81 0.000
9 IFI44L interferon-induced protein 44-like Blood + 3.58 0.000
10 USP41 ubiquitin specific peptidase 41 Blood + 3.40 0.000
11 HESX1 HESX homeobox 1 Blood + 3.22 0.000
12 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 Blood + 3.08 0.000
Search GEO for disease gene expression data for Systemic Lupus Erythematosus.

Pathways for Systemic Lupus Erythematosus

Pathways related to Systemic Lupus Erythematosus according to KEGG:

37
# Name Kegg Source Accession
1 Systemic lupus erythematosus hsa05322

GO Terms for Systemic Lupus Erythematosus

Cellular components related to Systemic Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CTLA4 ENG FCGR2B PDCD1

Biological processes related to Systemic Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.83 C4A C4B CR2 IRF5 TLR5
2 immune response GO:0006955 9.8 CR2 CTLA4 FCGR2B IL10 TNFSF4
3 regulation of complement activation GO:0030449 9.67 C4A C4B CR2
4 inflammatory response GO:0006954 9.63 C4A C4B FCGR2B IL10 TLR5 TNFSF4
5 negative regulation of immune response GO:0050777 9.48 CTLA4 FCGR2B
6 regulation of innate immune response GO:0045088 9.46 FCGR2B PTPN22
7 regulation of adaptive immune response GO:0002819 9.37 FCGR2B TNFSF4
8 negative regulation of regulatory T cell differentiation GO:0045590 9.32 CTLA4 TNFSF4
9 positive regulation of apoptotic cell clearance GO:2000427 9.26 C4A C4B
10 immune system process GO:0002376 9.17 C4A C4B CR2 CTLA4 IRF5 PTPN22
11 negative regulation of B cell proliferation GO:0030889 9.13 CTLA4 FCGR2B IL10

Molecular functions related to Systemic Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 IgG binding GO:0019864 8.96 FCGR2A FCGR2B
2 complement binding GO:0001848 8.62 C4B CR2

Sources for Systemic Lupus Erythematosus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....